Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s pregnancy/fetal toxicity claims are directly supported by the provided FDA label excerpts (Sections 5.1, 8.1, and 17) with no contradictions or omissions material to the pregnancy risk communication.
Category Scores
Accurate Statements
ENTRESTO can cause fetal harm when administered to a pregnant woman.
Supported by label 5.1 Fetal Toxicity and 8.1 Pregnancy risk summary ("ENTRESTO can cause fetal harm when administered to a pregnant woman.").
Use of drugs that act on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death.
Supported by label 5.1 (trimester-specific renal function reduction and morbidity/mortality).
When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO.
Supported by label 5.1 and 8.1 (discontinue ENTRESTO and consider alternative therapy).
If there is no appropriate alternative and therapy is considered lifesaving for the mother, advise the pregnant woman of the potential risk to the fetus.
Supported by label 5.1 and 8.1 (lifesaving for mother; advise potential fetal risk).
Oligohydramnios in pregnant women using renin-angiotensin system drugs in the second and third trimesters can result in reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations (including skull hypoplasia), hypotension, and death.
Supported by label 8.1 Clinical Considerations under Fetal/Neonatal Adverse Reactions.
Perform serial ultrasound examinations to assess the intra-amniotic environment and consider fetal testing based on gestational week; if oligohydramnios is observed, consider alternative drug treatment.
Supported by label 8.1 Clinical Considerations.
Closely observe neonates with histories of in utero exposure to ENTRESTO for hypotension, oliguria, and hyperkalemia.
Supported by label 8.1 Clinical Considerations (neonatal monitoring).
Advise female patients of childbearing age about the consequences of exposure during pregnancy and ask patients to report pregnancies to their physicians as soon as possible.
Supported by label 17 Patient Counseling Information (Pregnancy counseling).
Unsupported Statements
Contradictions
Important Omissions
No mention of the label’s counseling about asking patients to report pregnancies 'as soon as possible' beyond the general statement in the provided response (the response did include this item, so this is not applicable).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
All pregnancy/fetal toxicity statements included are consistent with the supplied label excerpts and include key label-directed actions (discontinue/alternative therapy; counseling; neonatal monitoring). No unsafe or contradicted claims were present.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response includes only pregnancy/fetal toxicity-related content; if additional label elements are required (e.g., boxed warning status, contraindications, full precautions), they are not evaluated here because they were not claimed in the response.
Suggested Improvement
If expanding beyond pregnancy counseling, explicitly evaluate and cite the relevant additional label sections (e.g., contraindications, specific warnings/precautions, boxed warnings if applicable) rather than limiting to fetal toxicity/pregnancy excerpts.